The prevalence of patent interferences in gene technology

Loading...
Thumbnail Image
Penn collection
Center for Bioethics Papers
Degree type
Discipline
Subject
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Henry, Michelle R
Contributor
Abstract

Unlike all other countries in the world, the United States awards patents to the first to invent, not to the first to file an application for a patent. In cases where two or more inventors submit patent applications claiming the same invention, an interference may be declared. Interference is the process by which the US Patent & Trademark Office (USPTO; Washington, DC, USA) determines which of the applicants was the first to invent and diligently reduce the invention to practice. More than half of these are resolved in favor of the inventor who was the first-to-file, raising questions about whether this unique system is worth retaining. Interferences are relatively rare. For the period 1998-2002, an average of four interferences were declared for every 10,000 patent applications filed. Data we have gathered suggest that interference proceedings in gene discovery and biotechnology are much more prevalent than other areas of technology. The resulting legal fees are costing the biotechnology industry millions of dollars each year.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2004-02-01
Journal title
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Postprint version. Published in Nature Biotechnology, Volume 22, Issue 2, February 2004, pages 153-154. Publisher URL: http://dx.doi.org/10.1038/nbt0204-153
Recommended citation
Collection